| scholarly article | Q13442814 |
| P50 | author | Xiaoming Ouyang | Q59750692 |
| P2093 | author name string | Jeffrey W Tyner | |
| Shannon K McWeeney | |||
| Molly Kulesz-Martin | |||
| Sara A Courtneidge | |||
| Daniel Clayburgh | |||
| Ashley Barling | |||
| Sophia Jeng | |||
| Toni M West | |||
| Gabrielle Choonoo | |||
| Aletha Lesch | |||
| Christina Zheng | |||
| P2860 | cites work | Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor | Q24314620 |
| ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) | Q24336482 | ||
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| Crizotinib: from discovery to accelerated development to front-line treatment | Q26738385 | ||
| Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase | Q27704817 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors | Q27853214 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Fiji: an open-source platform for biological-image analysis | Q27860912 | ||
| Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells | Q28250203 | ||
| Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Inhibitors of the anaplastic lymphoma kinase | Q28267124 | ||
| Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system | Q28304840 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| Towards a knowledge-based Human Protein Atlas | Q29617987 | ||
| Evidence-Based Precision Oncology with the Cancer Targetome. | Q47893147 | ||
| Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels | Q54586347 | ||
| Intermediate filament proteins as distinguishing markers of cell type and differentiated state in cultured human urinary tract epithelia | Q69852019 | ||
| Steady-state cultures of human skin | Q71438980 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q88151876 | ||
| Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells | Q30424348 | ||
| In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy | Q30493990 | ||
| Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes | Q33669979 | ||
| The quest to overcome resistance to EGFR-targeted therapies in cancer | Q33725976 | ||
| A Functional Nuclear Epidermal Growth Factor Receptor, Src and Stat3 Heteromeric Complex in Pancreatic Cancer Cells | Q33900776 | ||
| mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations | Q34049613 | ||
| Understanding resistance to EGFR inhibitors-impact on future treatment strategies | Q34088424 | ||
| Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening | Q34307423 | ||
| Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. | Q34938204 | ||
| Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells | Q35063410 | ||
| Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | Q35575978 | ||
| Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck | Q35640310 | ||
| Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture | Q36215866 | ||
| EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. | Q36745876 | ||
| Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression | Q36798731 | ||
| Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas | Q37065337 | ||
| RNAi screen for rapid therapeutic target identification in leukemia patients | Q37187716 | ||
| Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. | Q37432540 | ||
| Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma | Q37736496 | ||
| Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer | Q38254567 | ||
| Co-regulation of B-Myb expression by E2F1 and EGF receptor | Q38318606 | ||
| FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. | Q38371186 | ||
| A simple hanging drop cell culture protocol for generation of 3D spheroids | Q38759320 | ||
| Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor | Q39112711 | ||
| New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors | Q39205322 | ||
| Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma | Q39594577 | ||
| Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients | Q39805159 | ||
| Nuclear EGFR contributes to acquired resistance to cetuximab | Q39812008 | ||
| Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway | Q40410769 | ||
| Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. | Q40424263 | ||
| Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor | Q40435873 | ||
| Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. | Q42315652 | ||
| Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, | Q42710837 | ||
| GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers | Q43262263 | ||
| ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. | Q44183110 | ||
| Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. | Q44260431 | ||
| FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets | Q44535930 | ||
| A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer | Q45007278 | ||
| Cellular targets of gefitinib | Q45253719 | ||
| Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. | Q46477039 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P921 | main subject | head and neck squamous cell carcinoma | Q18348812 |
| P304 | page(s) | 921-933 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models | |
| P478 | volume | 19 |
Search more.